Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02984163
Other study ID # HREBA.CC-16-0905
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 9, 2017
Est. completion date June 30, 2024

Study information

Verified date July 2023
Source University of Alberta
Contact Margaret L McNeely, PT, PhD
Phone 1-780-248-1531
Email mmcneely@ualberta.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this proposed 5-year hybrid effectiveness and implementation study is to evaluate the relative benefit from, and implementation of an Alberta wide clinic-to-community-based cancer and exercise model of care - the Alberta Cancer Exercise (ACE) Program. The investigators hypothesize that the strategy will improve the physical well-being and QoL of survivors (on and off cancer treatment) while preventing the development of secondary cancers.


Description:

A total of 2500 adult cancer survivors will be enrolled in the 5-year study. The investigators will build capacity by expanding ACE training and programming to sites beyond the large urban centers. The investigators plan for implementation in 7 Alberta YMCAs and/or City Recreation facilities within 3 years, as well as to formally establish partnerships within AHS to build further capacity across the province within existing AHS programming (e.g., CancerControl Rehab Services, Alberta Healthy Living Program and Primary Care Network). Virtual and supported home-based options will be available as an alternative. Eligible and consenting participants will be screened for exercise safety, and following fitness testing will be triaged to appropriate exercise programming in their home or community. The exercise intervention will take place at the survivor's home, YMCAs and municipal fitness centres across the province. The supported home-based and community-based exercise program will be administered by exercise specialists who have undergone the ACE Cancer and Exercise: Training for Fitness Professionals course. Survivors will take part in a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for an 8-to-12-week period. Effectiveness outcomes include physical fitness, physical activity, quality of life, and healthcare utilization. These outcomes are known factors associated with the secondary prevention of cancer. The RE-AIM framework will be used to evaluate program reach, effectiveness, adoption, implementation and maintenance. The Alberta Quality Matrix for Health will serve as a framework to inform program sustainability beyond the funding period. Through this research, the investigators will better understand the effectiveness of the ACE program, and evaluate processes to support future implementation and sustainability.


Recruitment information / eligibility

Status Recruiting
Enrollment 2500
Est. completion date June 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. have a diagnosis of cancer; 2. be over the age of 18 years; 3. be able to participate in low-intensity levels of activity at minimum; 4. be pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), or have received cancer treatment within the past 3 years; or have ongoing significant cancer or treatment-related impairments (requiring supportive exercise intervention); 5. be able to provide informed written consent in English. Exclusion criteria: 1) Inability or deemed unsafe to participate in physical activity program -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.

Locations

Country Name City State
Canada University of Calgary/ Tom Baker Cancer Centre Calgary Alberta
Canada University of Alberta & Cross Cancer Institute Edmonton Alberta

Sponsors (5)

Lead Sponsor Collaborator
University of Alberta Alberta Health services, Cross Cancer Institute, Tom Baker Cancer Centre, University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Home-based programming stepping test 2-minute stepping test Baseline to One-year
Other 1RM or 8RM strength (optional) Change in bench press, vertical row and leg press strength (kg) Baseline to One-year
Other Muscular endurance test (optional) Change in number of push-ups Baseline to One-year
Other Core endurance test (optional) Change in plank test (seconds held) Baseline to One-year
Primary Physical Activity Minutes Per Week Change in number of participants meeting Guidelines for Physical Activity of 150 minutes per week of moderate intensity exercise Baseline to One-year
Secondary Aerobic Endurance Change in 6 minute walk test distance (metres) Baseline to One-year
Secondary Quality of Life Cancer Specific Change in Functional Assessment of Cancer Therapy General Scale Baseline to One year
Secondary General Health-related Quality of Life Change in Rand Short Form (SF)-36 Baseline to One-year
Secondary Fatigue FACT-Fatigue subscale Baseline to One-year
Secondary Upper extremity grip strength Change in hand-grip dynamometry (kg) Baseline to One-year
Secondary Functional performance test Change in sit-to-stand (number in 30 seconds) Baseline to One-year
Secondary Upper extremity flexibility Change in active shoulder flexion range of motion (degrees) Baseline to One-year
Secondary Lower extremity flexibility Change in sit-and-reach test (cm) Baseline to One-year
Secondary Balance Change in one legged stance test (seconds) Baseline to One-year
Secondary Cost-effectiveness evaluation EQ-5D questionnaire Baseline to One-year
Secondary Exercise adherence Adherence to exercise programming (attendance at sessions) Baseline to 12-weeks
Secondary Body Composition Change in BMI Baseline to One-year
Secondary Waist and hip measurements Change in waist and hip circumference (cm) and change in waist-to-hip ratio Baseline to One-year
Secondary Program implementation and evaluation RE-AIM: program reach, effectiveness, adoption, implementation and maintenance Baseline to One-year
Secondary Adverse events Adverse event rates Baseline to One-year
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2